trending Market Intelligence /marketintelligence/en/news-insights/trending/87nan6ysjlj_vjvel5q7za2 content esgSubNav
In This List

Mylan acquires rights to 2 Novartis respiratory drugs in $463M deal

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Mylan acquires rights to 2 Novartis respiratory drugs in $463M deal

Mylan NV said it acquired the global rights to two Novartis AG respiratory drugs in a deal valued at about $463 million.

Novartis' TOBI Podhaler and TOBI solution are meant to treat cystic fibrosis, a progressive, genetic disease that causes persistent lung infections and limits the ability to breathe over time.

Mylan expects to settle approximately $240 million of the deal value this year.

The acquisition strengthens Mylan's portfolio of respiratory drugs.